2022年乳腺癌基础与转化研究进展

doi:10.19401/j.cnki.1007-3639.2023.02.001

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (2): 95-102.doi: 10.19401/j.cnki.1007-3639.2023.02.001

2022年乳腺癌基础与转化研究进展

王子彧(), 肖毅, 江一舟, 邵志敏()

复旦大学附属肿瘤医院乳腺外科/复旦大学乳腺癌研究所，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-01-08 修回日期:2023-01-24 出版日期:2023-02-28 发布日期:2023-03-22
通信作者: 邵志敏（ORCID：0000-0002-4503-148X），主任医师，教授，复旦大学肿瘤研究所所长、复旦大学乳腺癌研究所所长，复旦大学附属肿瘤医院大外科主任兼乳腺外科主任。
作者简介:王子彧（ORCID：0000-0002-3684-0816），复旦大学附属肿瘤医院博士研究生。
邵志敏，主任医师，教授，首批教育部长江学者特聘教授，国家杰出青年科学基金项目获得者，复旦大学特聘教授，复旦大学肿瘤研究所所长，复旦大学乳腺癌研究所所长，复旦大学附属肿瘤医院大外科主任兼乳腺外科主任。现任中国抗癌协会靶向治疗专业委员会主任委员，上海市抗癌协会副理事长；曾任中国抗癌协会乳腺癌专业委员会主任委员，中华医学会肿瘤学分会副主任委员。担任第八届亚洲乳腺癌协会主席，St. Gallen乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究，建立适合中国人群的早期筛查和诊疗流程，确立三阴性乳腺癌“复旦分型”和精准治疗策略，开展临床试验改善患者预后。已在Cancer Cell、Cell Metabolism、Cell Research、Journal of Clinical Oncology、JAMA Oncology、Journal of the National Cancer Institute等重要期刊上发表论著500余篇，被引用逾8 000次，主编专著10部。多次获得国家科技进步二等奖，教育部科技进步一、二等奖，卫健委科技进步一等奖，上海市科技进步一、二、三等奖，领衔团队入选教育部创新团队。先后主持国家自然科学基金重大项目、国家卫健委临床重点项目等国家级及省部级项目50余项。

Advances in fundamental and translational breast cancer research in 2022

WANG Ziyu(), XIAO Yi, JIANG Yizhou, SHAO Zhimin()

Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-01-08 Revised:2023-01-24 Published:2023-02-28 Online:2023-03-22
Contact: SHAO Zhimin

摘要/Abstract

摘要：

世界卫生组织（World Health Organization，WHO）国际癌症研究机构发布的数据显示，乳腺癌现已成为全球女性发病率最高的恶性肿瘤，严重威胁女性健康。2022年乳腺癌基础与转化研究领域进展颇丰，深化了对乳腺癌分子本质的认识，为乳腺癌精准治疗提供了新的思路。本文从肿瘤代谢、肿瘤微环境、微生物与肿瘤、肿瘤转移、肿瘤耐药与药物筛选、多组学研究、人工智能共7个方面对2022年乳腺癌基础与转化研究的年度进展进行总结，并对乳腺癌研究未来的发展方向进行展望，以期为乳腺癌研究的进一步深化提供参考。

关键词: 乳腺肿瘤, 基础与转化研究, 研究进展

Abstract:

According to the data released by the International Cancer Research Institute of the World Health Organization (WHO), breast cancer is the malignant tumor with the highest incidence rate in women, and seriously endangers women's health.Many impressive advances have been achieved in fundamental and translational research of breast cancer, which deepened the understanding of the molecular nature of breast cancer and provided new scientific strategies for the precision treatment of breast cancer. This paper summarized the annual advances in fundamental and translational breast cancer research in 2022 in seven sections: tumor metabolism, tumor microenvironment, microbes and tumors, tumor metastasis, tumor drug resistance and drug screening, multi-omics research and artificial intelligence. Furthermore, we proposed an outlook on the future directions of breast cancer research to provide a reference for future studies.

Key words: Breast cancer, Fundamental and translational research, Research advances

中图分类号:

R737.9

王子彧, 肖毅, 江一舟, 邵志敏. 2022年乳腺癌基础与转化研究进展[J]. 中国癌症杂志, 2023, 33(2): 95-102.

WANG Ziyu, XIAO Yi, JIANG Yizhou, SHAO Zhimin. Advances in fundamental and translational breast cancer research in 2022[J]. China Oncology, 2023, 33(2): 95-102.

参考文献 71

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	JIANG H M, WEI H M, WANG H, et al. Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer[J]. Cell Death Dis, 2022, 13(3): 206. doi: 10.1038/s41419-022-04632-z pmid: 35246504
[3]	ZHU W J, CHEN X, GUO X Y, et al. Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer[J]. Cancer Res, 2022, 82(5): 805-818. doi: 10.1158/0008-5472.CAN-21-1179 pmid: 35031573
[4]	CHEN X M, LUO R, ZHANG Y M, et al. Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer[J]. Nat Commun, 2022, 13(1): 7160. doi: 10.1038/s41467-022-34702-x pmid: 36418319
[5]	PARIDA P K, MARQUEZ-PALENCIA M, NAIR V, et al. Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness[J]. Cell Metab, 2022, 34(1): 90-105.e7. doi: 10.1016/j.cmet.2021.12.001 pmid: 34986341
[6]	GOMES A P, ILTER D, LOW V, et al. Altered propionate metabolism contributes to tumour progression and aggressiveness[J]. Nat Metab, 2022, 4(4): 435-443. doi: 10.1038/s42255-022-00553-5 pmid: 35361954
[7]	GONG Z, LI Q, SHI J Y, et al. Lipid-laden lung mesenchymal cells foster breast cancer metastasis via metabolic reprogramming of tumor cells and natural killer cells[J]. Cell Metab, 2022, 34(12): 1960-1976.e9. doi: 10.1016/j.cmet.2022.11.003 pmid: 36476935
[8]	DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. doi: 10.1016/j.cell.2012.03.042 pmid: 22632970
[9]	TANG D L, CHEN X, KANG R, et al. Ferroptosis: molecular mechanisms and health implications[J]. Cell Res, 2021, 31(2): 107-125. doi: 10.1038/s41422-020-00441-1 pmid: 33268902
[10]	LI H Y, YANG P H, WANG J H, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk[J]. J Hematol Oncol, 2022, 15(1): 2. doi: 10.1186/s13045-021-01223-x
[11]	WU M M, ZHANG X, ZHANG W J, et al. Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis[J]. Nat Commun, 2022, 13(1): 1371. doi: 10.1038/s41467-022-29018-9 pmid: 35296660
[12]	ZOU Y T, ZHENG S Q, XIE X H, et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer[J]. Nat Commun, 2022, 13(1): 2672. doi: 10.1038/s41467-022-30217-7 pmid: 35562334
[13]	YANG F, XIAO Y, DING J H, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy[J]. Cell Metab, 2023, 35(1): 84-100.e8. doi: 10.1016/j.cmet.2022.09.021
[14]	ZHANG H L, HU B X, LI Z L, et al. PKCβⅡ phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis[J]. Nat Cell Biol, 2022, 24(1): 88-98. doi: 10.1038/s41556-021-00818-3
[15]	XIE Y Z, WANG B Y, ZHAO Y N, et al. Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis[J]. J Hematol Oncol, 2022, 15(1): 72. doi: 10.1186/s13045-022-01297-1
[16]	LI K, LIN C C, LI M H, et al. Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy[J]. ACS Nano, 2022, 16(2): 2381-2398. doi: 10.1021/acsnano.1c08664 pmid: 35041395
[17]	YANG J, JIA Z G, ZHANG J, et al. Metabolic intervention nanoparticles for triple-negative breast cancer therapy via overcoming FSP1-mediated ferroptosis resistance[J]. Adv Healthc Mater, 2022, 11(13): e2102799.
[18]	PAN W L, TAN Y, MENG W, et al. Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework[J]. Biomaterials, 2022, 283: 121449. doi: 10.1016/j.biomaterials.2022.121449
[19]	ZHOU A W, FANG T L, CHEN K R, et al. Biomimetic activator of sonodynamic ferroptosis amplifies inherent peroxidation for improving the treatment of breast cancer[J]. Small, 2022, 18(12): e2106568.
[20]	SEUNG E, XING Z, WU L, et al. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells[J]. Nature, 2022, 603(7900): 328-334. doi: 10.1038/s41586-022-04439-0
[21]	NALIO RAMOS R, MISSOLO-KOUSSOU Y, GERBER-FERDER Y, et al. Tissue-resident FOLR2⁺ macrophages associate with CD8⁺ T cell infiltration in human breast cancer[J]. Cell, 2022, 185(7): 1189-1207.e25. doi: 10.1016/j.cell.2022.02.021
[22]	NIXON B G, KUO F S, JI L L, et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer[J]. Immunity, 2022, 55(11): 2044-2058.e5. doi: 10.1016/j.immuni.2022.10.002
[23]	BLOMBERG O S, SPAGNUOLO L, GARNER H, et al. IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer[J]. Cancer Cell, 2023, 41(1): 106-123.e10. doi: 10.1016/j.ccell.2022.11.014
[24]	KAY E J, PATERSON K, RIERA-DOMINGO C, et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix[J]. Nat Metab, 2022, 4(6): 693-710. doi: 10.1038/s42255-022-00582-0 pmid: 35760868
[25]	PAPANICOLAOU M, PARKER A L, YAM M, et al. Temporal profiling of the breast tumour microenvironment reveals collagen Ⅻ as a driver of metastasis[J]. Nat Commun, 2022, 13(1): 4587. doi: 10.1038/s41467-022-32255-7
[26]	HONGU T, PEIN M, INSUA-RODRÍGUEZ J, et al. Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs[J]. Nat Cancer, 2022, 3(4): 486-504. doi: 10.1038/s43018-022-00353-6
[27]	ZHU Q Z, ZHU Y, HEPLER C, et al. Adipocyte mesenchymal transition contributes to mammary tumor progression[J]. Cell Rep, 2022, 40(11): 111362. doi: 10.1016/j.celrep.2022.111362
[28]	WANG Y Q, XIE H L, WU Y, et al. Bioinspired lipoproteins of furoxans-oxaliplatin remodel physical barriers in tumor to potentiate T-cell infiltration[J]. Adv Mater, 2022, 34(14): e2110614.
[29]	NIA H T, MUNN L L, JAIN R K. Physical traits of cancer[J]. Science, 2020, 370(6516): eaaz0868. doi: 10.1126/science.aaz0868
[30]	BERA K, KIEPAS A, GODET I, et al. Extracellular fluid viscosity enhances cell migration and cancer dissemination[J]. Nature, 2022, 611(7935): 365-373. doi: 10.1038/s41586-022-05394-6
[31]	ROMANI P, NIRCHIO N, ARBOIT M, et al. Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance[J]. Nat Cell Biol, 2022, 24(2): 168-180. doi: 10.1038/s41556-022-00843-w pmid: 35165418
[32]	HANAHAN D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. doi: 10.1158/2159-8290.CD-21-1059 pmid: 35022204
[33]	HIEKEN T J, CHEN J, HOSKIN T L, et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease[J]. Sci Rep, 2016, 6: 30751. doi: 10.1038/srep30751 pmid: 27485780
[34]	NEJMAN D, LIVYATAN I, FUKS G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494): 973-980. doi: 10.1126/science.aay9189 pmid: 32467386
[35]	WANG H, RONG X Y, ZHAO G, et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer[J]. Cell Metab, 2022, 34(4): 581-594.e8. doi: 10.1016/j.cmet.2022.02.010 pmid: 35278352
[36]	FU A K, YAO B Q, DONG T T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer[J]. Cell, 2022, 185(8): 1356-1372.e26. doi: 10.1016/j.cell.2022.02.027 pmid: 35395179
[37]	DENG H, MUTHUPALANI S, ERDMAN S, et al. Translocation of helicobacter hepaticus synergizes with myeloid-derived suppressor cells and contributes to breast carcinogenesis[J]. Oncoimmunology, 2022, 11(1): 2057399. doi: 10.1080/2162402X.2022.2057399
[38]	NARUNSKY-HAZIZA L, SEPICH-POORE G D, LIVYATAN I, et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions[J]. Cell, 2022, 185(20): 3789-3806.e17. doi: 10.1016/j.cell.2022.09.005
[39]	DOHLMAN A B, KLUG J, MESKO M, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors[J]. Cell, 2022, 185(20): 3807-3822.e12. doi: 10.1016/j.cell.2022.09.015 pmid: 36179671
[40]	XIAO S S, SHI H, ZHANG Y, et al. Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer[J]. J Nanobiotechnol, 2022, 20(1): 178. doi: 10.1186/s12951-022-01373-1 pmid: 35366890
[41]	NGUYEN B, FONG C, LUTHRA A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25, 000 patients[J]. Cell, 2022, 185(3): 563-575.e11. doi: 10.1016/j.cell.2022.01.003
[42]	GARCIA-RECIO S, HINOUE T, WHEELER G L, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis[J]. Nat Cancer, 2022[Epub ahead of print].
[43]	GONG Z, LI Q, SHI J Y, et al. Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment[J]. Immunity, 2022, 55(8): 1483-1500.e9. doi: 10.1016/j.immuni.2022.07.001 pmid: 35908547
[44]	QI M Y, XIA Y, WU Y J, et al. Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression[J]. Nat Commun, 2022, 13(1): 897. doi: 10.1038/s41467-022-28438-x pmid: 35173168
[45]	GUTWILLIG A, SANTANA-MAGAL N, FARHAT-YOUNIS L, et al. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy[J]. Elife, 2022, 11: e80315. doi: 10.7554/eLife.80315
[46]	BALDOMINOS P, BARBERA-MOURELLE A, BARREIRO O, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche[J]. Cell, 2022, 185(10): 1694-1708.e19. doi: 10.1016/j.cell.2022.03.033
[47]	CHANG C A, JEN J, JIANG S W, et al. Ontogeny and vulnerabilities of drug-tolerant persisters in HER2⁺ breast cancer[J]. Cancer Discov, 2022, 12(4): 1022-1045. doi: 10.1158/2159-8290.CD-20-1265
[48]	MARSOLIER J, PROMPSY P, DURAND A, et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer[J]. Nat Genet, 2022, 54(4): 459-468. doi: 10.1038/s41588-022-01047-6 pmid: 35410383
[49]	LIU X W, LU Y W, HUANG J Y, et al. CD16⁺ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition[J]. Cancer Cell, 2022, 40(11): 1341-1357.e13. doi: 10.1016/j.ccell.2022.10.015
[50]	LI H Z, XIAO Y, LI Q, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1[J]. Cancer Cell, 2022, 40(1): 36-52.e9. doi: 10.1016/j.ccell.2021.11.002
[51]	MA S J, ZHAO Y, LEE W C, et al. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple-negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy[J]. Nat Commun, 2022, 13(1): 4118. doi: 10.1038/s41467-022-31764-9
[52]	JAAKS P, COKER E A, VIS D J, et al. Effective drug combinations in breast, colon and pancreatic cancer cells[J]. Nature, 2022, 603(7899): 166-173. doi: 10.1038/s41586-022-04437-2
[53]	GUILLEN K P, FUJITA M, BUTTERFIELD A J, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology[J]. Nat Cancer, 2022, 3(2): 232-250. doi: 10.1038/s43018-022-00337-6
[54]	JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5. doi: 10.1016/j.ccell.2019.02.001
[55]	BERTUCCI F, NG C K Y, PATSOURIS A, et al. Genomic characterization of metastatic breast cancers[J]. Nature, 2019, 569(7757): 560-564. doi: 10.1038/s41586-019-1056-z
[56]	MERTINS P, MANI D R, RUGGLES K V, et al. Proteogenomics connects somatic mutations to signalling in breast cancer[J]. Nature, 2016, 534(7605): 55-62. doi: 10.1038/nature18003
[57]	CURTIS C, SHAH S P, CHIN S F, et al. The genomic and transcriptomic architecture of 2 000 breast tumours reveals novel subgroups[J]. Nature, 2012, 486(7403): 346-352. doi: 10.1038/nature10983
[58]	PEREIRA B, CHIN S F, RUEDA O M, et al. Erratum: the somatic mutation profiles of 2, 433 breast cancers refine their genomic and transcriptomic landscapes[J]. Nat Commun, 2016, 7: 11908. doi: 10.1038/ncomms11908
[59]	BARECHE Y, VENET D, IGNATIADIS M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis[J]. Ann Oncol, 2018, 29(4): 895-902. doi: S0923-7534(19)45470-7 pmid: 29365031
[60]	XIAO Y, MA D, YANG Y S, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer[J]. Cell Res, 2022, 32(5): 477-490. doi: 10.1038/s41422-022-00614-0 pmid: 35105939
[61]	JIANG L, YOU C, XIAO Y, et al. Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer[J]. Cell Rep Med, 2022, 3(7): 100694.
[62]	LOMAKIN A, SVEDLUND J, STRELL C, et al. Spatial genomics maps the structure, nature and evolution of cancer clones[J]. Nature, 2022, 611(7936): 594-602. doi: 10.1038/s41586-022-05425-2
[63]	FUNNELL T, O'FLANAGAN C H, WILLIAMS M J, et al. Single-cell genomic variation induced by mutational processes in cancer[J]. Nature, 2022, 612(7938): 106-115. doi: 10.1038/s41586-022-05249-0
[64]	MARTINI R, DELPE P, CHU T R, et al. African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent[J]. Cancer Discov, 2022, 12(11): 2530-2551. doi: 10.1158/2159-8290.CD-22-0138
[65]	STRAND S H, RIVERO-GUTIÉRREZ B, HOULAHAN K E, et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: analysis of TBCRC 038 and RAHBT cohorts[J]. Cancer Cell, 2022, 40(12): 1521-1536.e7. doi: 10.1016/j.ccell.2022.10.021
[66]	LIPS E H, KUMAR T, MEGALIOS A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer[J]. Nat Genet, 2022, 54(6): 850-860. doi: 10.1038/s41588-022-01082-3
[67]	RISOM T, GLASS D R, AVERBUKH I, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma[J]. Cell, 2022, 185(2): 299-310.e18. doi: 10.1016/j.cell.2021.12.023 pmid: 35063072
[68]	YALA A, MIKHAEL P G, LEHMAN C, et al. Optimizing risk-based breast cancer screening policies with reinforcement learning[J]. Nat Med, 2022, 28(1): 136-143. doi: 10.1038/s41591-021-01599-w pmid: 35027757
[69]	WANG Y, ACS B, ROBERTSON S, et al. Improved breast cancer histological grading using deep learning[J]. Ann Oncol, 2022, 33(1): 89-98. doi: 10.1016/j.annonc.2021.09.007
[70]	SAMMUT S J, CRISPIN-ORTUZAR M, CHIN S F, et al. Multi-omic machine learning predictor of breast cancer therapy response[J]. Nature, 2022, 601(7894): 623-629. doi: 10.1038/s41586-021-04278-5
[71]	ZHAO S, YAN C Y, LV H, et al. Deep learning framework for comprehensive molecular and prognostic stratifications of triple-negative breast cancer[J]. Fundam Res, 2022[Epub ahead of print].

2022年乳腺癌基础与转化研究进展

Advances in fundamental and translational breast cancer research in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 71

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116.
[2]	杨贻兰, 赵旭, 陈星星, 汪宣伊, 金恺睿, 章真, 邵志敏, 郭小毛, 俞晓立. 乳腺导管原位癌的单中心预后分析[J]. 中国癌症杂志, 2022, 32(3): 228-233.
[3]	李语婕, 陈颢. 靶向TROP2在胰腺癌治疗中的潜力[J]. 中国癌症杂志, 2022, 32(3): 268-273.
[4]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[5]	尹志海, 汪隽琦, 孟怡然, 许　青, 杨昭志. 患者生理特征参数对乳腺癌调强放疗摆位误差影响的研究[J]. 中国癌症杂志, 2021, 31(3): 198-202.
[6]	李芷君, 徐兵河. 乳腺癌芳香化酶抑制剂耐药的研究进展[J]. 中国癌症杂志, 2021, 31(2): 81-89.
[7]	孙瑞红,王　翔,沈丽娟,孟凡华,尹化斌 . 乳腺癌患者MRI体素内不相干运动成像中感兴趣区选择方法对参数一致性的影响[J]. 中国癌症杂志, 2019, 29(9): 700-708.
[8]	杨　珂，郑　容，林岩松. 儿童青少年甲状腺癌诊治指南解读及其进展——核医学部分[J]. 中国癌症杂志, 2019, 29(6): 401-411.
[9]	毕钊，刘静静，陈鹏，刘雁冰，赵桐，孙晓，邱鹏飞，王永胜. 乳腺癌新辅助化疗后内乳区前哨淋巴结活检研究[J]. 中国癌症杂志, 2019, 29(2): 131-135.
[10]	张凤春,左丽,马越,等. AJCC第7版与第8版分期对乳腺癌患者预后预测的比较分析[J]. 中国癌症杂志, 2019, 29(1): 45-51.
[11]	中国抗癌协会乳腺癌专业委员会（CBCS）中国医师协会外科医师分会乳腺外科医师专委会（CSBS）. 乳腺肿瘤整形与乳房重建专家共识（2018年版）[J]. 中国癌症杂志, 2018, 28(6): 439-480.
[12]	张　燕,孙　晓,赵　桐,等. 术中快速预测乳腺癌非前哨淋巴结转移模型的建立与验证研究[J]. 中国癌症杂志, 2017, 27(5): 368-375.
[13]	孙瑞红,蒋朝霞,孟凡华,等. 体素内不相干运动成像鉴别乳腺良恶性病变的价值并与定量动态增强MRI对比[J]. 中国癌症杂志, 2017, 27(10): 795-800.
[14]	王晓迪,江泽飞. 再议乳腺癌内分泌治疗10项热点问题[J]. 中国癌症杂志, 2017, 27(10): 822-828.
[15]	贾振亚,胡夕春,傅凤鸣,等. 艾日布林诱发毛细血管渗漏综合征1例[J]. 中国癌症杂志, 2016, 26(2): 198-200.